Facilitating Optimal Outcomes for the Management of Retinal Diseases: Health Plan Best Practice Recommendations
A 3-Track CE Webcast Series
Track 1: Spotlight on Diabetic Retinopathy & Diabetic Macular Edema
Track 2: Spotlight on Age-Related Macular Degeneration
Track 3: Spotlight on Retinal Vein Occlusion

Learn About:

• Pharmacologic treatment options for retinal diseases
• Evidence supporting treat-and-extend strategies with anti-VEGF therapies
• Payer/provider decision-support tools for proactive and personalized treatment approaches

Expert Faculty Presenters:

Jeffrey Dunn, PharmD, MBA (Chair) Chief Clinical Officer Cooperative Benefits Group (CBG) Click here for biography W. Lloyd Clark, MD (Track 1) Assistant Clinical Professor of Ophthalmology University of South Carolina School of Medicine Palmetto Retina Center Click here for biography Dana McCormick, RPh, FAMCP (Track 1) Director of Pharmacy Blue Cross Blue Shield of Texas Click here for biography Ryan Bitton, PharmD, MBA (Track 2) Senior Director, Pharmacy Services Health Plan of Nevada Click here for biography David M. Brown, MD (Track 2, 3) Retina Specialist Retina Consultants of Texas Click here for biography Jason Parrott, MBA (Track 3) SVP Enterprise Growth and Partnerships Vida Health Click here for biography

Target Audience
The target audience consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
For managed care professionals, retinal diseases—specifically, age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and diabetic retinopathy (DR) —present a substantial challenge and as such there are unmet educational needs. Payers, tasked with weighing considerations of efficacy and drug costs, while balancing formulary placement, step therapy, site-of-care, and member access require instruction to implement optimal drug management initiatives and benefit design schema to facilitate patient access and outcomes in retinal diseases.

Educational Objectives for Track 1
After completing this activity, the participant should be better able to:

• Describe evidence-based considerations in applying available screening modalities and appropriate treatment strategies for optimal outcomes in retinal diseases
• Differentiate between available pharmacologic treatment options for retinal diseases in terms of efficacy, safety, and dosing regimen
• Discuss findings from the Protocol T study differentiating the efficacy of anti-VEGF therapies for retinal diseases
• Outline evidence supporting treat-and-extend strategies with anti-VEGF therapies and assess associated costs
• Implement medical and pharmacy benefit design strategies that facilitate patient access to evidence-based treatment options for retinal diseases
• Apply collaborative payer/provider decision-support tools for proactive and personalized treatment approaches among plan members with retinal diseases

Educational Objectives for Tracks 2 and 3
After completing this activity, the participant should be better able to:

• Describe evidence-based considerations in applying available screening modalities and appropriate treatment strategies for optimal outcomes in retinal diseases
• Differentiate between available pharmacologic treatment options for retinal diseases in terms of efficacy, safety, and dosing regimen
• Outline evidence supporting treat-and-extend strategies with anti-VEGF therapies and assess associated costs
• Implement medical and pharmacy benefit design strategies that facilitate patient access to evidence-based treatment options for retinal diseases
• Apply collaborative payer/provider decision-support tools for proactive and personalized treatment approaches among plan members with retinal diseases

Accreditation Statement

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Medical Education Resources and Impact Education, LLC. Medical Education Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• Track 1: 1.5 CME credit
• Track 2: 1.5 CME credit
• Track 3: 1.5 CME credit

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 4.5 contact hour(s) (0.45 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1:

• UAN: JA0003680-9999-22-015-L01-P
• Contact Hour:  1.5
• Activity Type: Knowledge-based

Track 2:

• UAN: JA0003680-9999-22-014-L01-P
• Contact Hour: 1.5
• Activity Type: Knowledge-based

Track 3:

• UAN: JA0003680-9999-22-016-L01-P
• Contact Hour: 1.5
• Activity Type: Knowledge-based

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 4.5 contact hours.

• Track 1: 1.5 CNE credit
• Track 2: 1.5 CNE credit
• Track 3: 1.5 CNE credit

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, Medical Education Resources, Inc. identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are mitigated by Medical Education Resources, Inc. to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The MER planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.